Structure-informed model selects antibody variants active against SARS-CoV-2 escape variants
ESM-IF1 scored substitutions in antibody–antigen complexes, and researchers experimentally screened variants of two clinical antibodies. The journal article reports up to 25-fold neutralization improvement against BQ.1.1 and up to 37-fold affinity improvement against XBB.1.5; these are distinct assays/variants. The preprint abstract reports a different neutralization figure, so this record uses journal values and does not backdate them to preprint v1.
Technology: ESM-IF1 inverse-folding protein model
Family ESM / ESMFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: PMC-hosted primary article reports experimental screening and improved neutralization/affinity results for antibody variants.
- Still unknown: Exact v1 result content and sequence-level overlap with earlier group studies not completely established; no clinical efficacy.
- AI role: Structure-informed inverse-folding scores guided substitutions followed by antibody binding and neutralization tests.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11616794/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: Primary source checked for identity, date, model role and bounded reported result..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.